Clinical Trials in PBC Going Forward

Christophe Corpechot

doi:10.1055/s-0039-1687852

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2019; 39(03): e1-e6
DOI: 10.1055/s-0039-1687852

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Clinical Trials in PBC Going Forward

Christophe Corpechot

¹Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis (MIVB-H), French Network for Pediatric and Adult Rare Liver Diseases (FILFOIE), Saint-Antoine Hospital, Assistance Publique – Hôpitaux de Paris (APHP) and Sorbonne University, Paris, France

› Institutsangaben

Abstract

New treatments for primary biliary cholangitis (PBC) are progressively emerging, including first and second generations of farnesoid X receptor and peroxisome proliferator-activated receptors agonists. Even though ursodeoxycholic acid monotherapy remains the standard of care treatment for PBC, these additional therapeutic options, already or soon to be available, lead us to revise our priorities and strategies with respect to future clinical trials. The present article is a personal view of where we currently stand in this field and where and how we should be going to achieve new progress.

Keywords

primary biliary cholangitis - obeticholic acid - bezafibrate - POISE - BEZURSO - surrogate marker

Volltext

Referenzen

References
1 Harms MH, Janssen Q, Adam R. , et al. Time trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. J Hepatol 2018; 68: S214
2 Nevens F, Andreone P, Mazzella G. , et al; POISE Study Group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016; 375 (07) 631-643
3 Corpechot C, Chazouillères O, Rousseau A. , et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med 2018; 378 (23) 2171-2181
4 Schramm C, Hirschfield G, Mason A. , et al. Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing phase 2 study. J Hepatol 2018; 68: S103
5 Jones D, Boudes PF, Swain MG. , et al. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol 2017; 2 (10) 716-726
6 Poupon RE, Balkau B, Eschwège E, Poupon R. ; UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324 (22) 1548-1554
7 Heathcote EJ, Cauch-Dudek K, Walker V. , et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19 (05) 1149-1156
8 Lindor KD, Dickson ER, Baldus WP. , et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106 (05) 1284-1290
9 Combes B, Carithers Jr RL, Maddrey WC. , et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22 (03) 759-766
10 Parés A, Caballería L, Rodés J. , et al; UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. J Hepatol 2000; 32 (04) 561-566
11 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67 (01) 145-172
12 Hirschfield GM, Dyson JK, Alexander GJM. , et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018; 67 (09) 1568-1594
13 Lindor KD, Bowlus CL, Boyer J. , et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; •••
14 Younossi ZM, Bernstein D, Shiffman ML. , et al. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol 2018; •••
15 Corpechot C, Abenavoli L, Rabahi N. , et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48 (03) 871-877
16 Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130 (03) 715-720
17 Kuiper EM, Hansen BE, de Vries RA. , et al; Dutch PBC Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136 (04) 1281-1287
18 Kumagi T, Guindi M, Fischer SE. , et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105 (10) 2186-2194
19 Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011; 55 (06) 1361-1367
20 Azemoto N, Kumagi T, Abe M. , et al. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis. Hepatol Res 2011; 41 (04) 310-317
21 Lammers WJ, Hirschfield GM, Corpechot C. , et al; Global PBC Study Group. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology 2015; 149 (07) 1804-1812.e4
22 Carbone M, Sharp SJ, Flack S. , et al; UK-PBC Consortium. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 2016; 63 (03) 930-950
23 Carbone M, Mells GF, Pells G. , et al; UK PBC Consortium. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013; 144 (03) 560-569.e7 , quiz e13–e14
24 Lammers WJ, van Buuren HR, Hirschfield GM. , et al; Global PBC Study Group. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147 (06) 1338-49.e5 , quiz e15
25 Bowlus C, Neff G, Aspinall R. , et al. Efficacy and safety of Seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis: 52-week analysis of an ongoing international, randomized, dose ranging phase 2 study. Hepatology 2018; 68: 1445A
26 Mayo MJ, Wigg AJ, Leggett BA. , et al. NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Commun 2018; 2 (09) 1037-1050
27 Hirschfield G, Kupcinskas L, Ott P. , et al. Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. J Hepatol 2018; 68: S38
28 Leuschner M, Maier KP, Schlichting J. , et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117 (04) 918-925
29 Rautiainen H, Kärkkäinen P, Karvonen AL. , et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005; 41 (04) 747-752
30 Fickert P, Hirschfield GM, Denk G. , et al; European PSC norUDCA Study Group. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol 2017; 67 (03) 549-558
31 Corpechot C. Primary biliary cirrhosis beyond ursodeoxycholic acid. Semin Liver Dis 2016; 36 (01) 15-26
32 Corpechot C, Carrat F, Poujol-Robert A. , et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012; 56 (01) 198-208
33 Mayo MJ, Parkes J, Adams-Huet B. , et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008; 48 (05) 1549-1557
34 Vergniol J, Boursier J, Coutzac C. , et al. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology 2014; 60 (01) 65-76
35 European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63 (01) 237-264
36 Carbone M, Nardi A, Flack S. , et al; Italian PBC Study Group and the UK–PBC Consortium. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. Lancet Gastroenterol Hepatol 2018; 3 (09) 626-634
37 Murillo Perez CF, Gulamhusein A, Corpechot C. , et al. Alkaline phosphatase normalization is associated with a decreased risk for liver transplantation and death in patients with primary biliary cholangitis. Hepatology 2018; 68: 1085A